Actively Recruiting
Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
Led by Institut Claudius Regaud · Updated on 2026-02-10
1050
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a translational, open-label, monocentric and prospective cohort study of participants with breast cancer aiming to create a combined ESPRESSO (= organelle properties) phenotype and spatial proteomics data collection encompassing four cohorts: * TN eBC = cohort A, * HER2+ eBC = cohort B, * Luminal eBC = cohort C, * dnMBC = cohort D. In total 1050 participants will be enrolled in the study. Laboratory analysis (including ESPRESSO technique) will be conducted on the biological specimen collected during this study. The primary objective is to describe the amount of fatty acids accumulated in lipid droplets, within the four cohorts. As a secondary objective, the analysis will expand to other organelles like lysosomal acidity and nuclear organization. The study is due to last 9 years (4 years of recruitment and 5 years of study participation)
CONDITIONS
Official Title
Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient (women or men) with histologically documented breast cancer
- Early Breast Cancer (eBC) or de novo metastatic breast cancer (dnMBC), regardless of immunohistochemical subtype
- Age 18 years or older at study entry
- Patient followed within a standard of care procedure or clinical trial
- ECOG performance status 0, 1, or 2
- Breast cancer treatment not started yet
- Patient able and willing to give informed consent and comply with study protocol
- Patient affiliated to a Social Health Insurance in France
You will not qualify if you...
- Known positive test for Hepatitis B virus, Hepatitis C virus, HIV, or Hanta virus
- Abnormal blood clotting preventing biopsy
- Previous or ongoing breast cancer treatment
- Bone metastases as the only biopsy site for dnMBC patients
- Conditions contraindicating blood sampling including hemoglobin below 8 g/dl
- Known additional malignancy that is active or requires treatment (except treated basal or squamous skin cancer or in situ cervical cancer)
- Pregnant or breastfeeding
- Psychological, familial, geographic, or social situations preventing consent or compliance
- Patient under legal guardianship or deprived of freedom by legal decision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France, 31059
Actively Recruiting
Research Team
F
Florence DALENC, MD, Professor
CONTACT
C
Camille FRANCHET, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here